Drug intelligence / Profile preview

Total Flavonoids of Fructus Aurantii Immaturus

Development stage: Preclinical
Lead developer: Jiangxi Qingfeng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Total Flavonoids of Fructus Aurantii Immaturus are extracted from the immature fruit of *Citrus aurantium* and have been studied for their effects on gastrointestinal health. They improve constipation by regulating miR-5100 and targeting Frizzled-2 (Fzd2), which helps in maintaining calcium balance and reducing autophagy in interstitial cells of Cajal (ICCs) [1]. They also alleviate symptoms of functional dyspepsia and have antioxidant properties [5].

Brand names: Aolanti
Other names: Aurantii Fructus Immaturus flavonoids (AFIF)

Targets

FZD2 (Frizzled Receptor 2)

Beyond the preview

Go deeper on Total Flavonoids of Fructus Aurantii Immaturus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Total Flavonoids of Fructus Aurantii Immaturus.

Explore the full profile